Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease
August 26, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
August 13, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Reports Second Quarter 2020 Financial Results and Business Update
August 06, 2020 07:00 ET
|
Cerecor Inc.
-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the...
Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric...
Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
August 04, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations
August 03, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS
July 21, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
June 11, 2020 13:30 ET
|
Cerecor Inc.
ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock
June 09, 2020 09:05 ET
|
Cerecor Inc.
ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
Cerecor Inc. Announces Proposed Public Offering of Common Stock
June 08, 2020 16:01 ET
|
Cerecor Inc.
ROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...